Status:
WITHDRAWN
Creatine Monohydrate Use for Preventing Altitude Induced Depression
Lead Sponsor:
Mike O'Callaghan Military Hospital
Conditions:
Depression
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
This study involves the use of an investigational drug called Creatine Monohydrate. This means that the drug has not yet been approved by the Food \& Drug Administration (FDA) for treatment of altitud...
Detailed Description
Subjects will be in this research study if they moved to Creech AFB from an elevation of less than 2.000 feet within the last month. The purpose of this study is to see if creatine monohydrate is effe...
Eligibility Criteria
Inclusion
- PATIENTS MUST BE ABLE TO GET CARE AT NELLIS AIR FORCE BASE (A MILITARY INSTALLATION) IN ORDER TO PARTICIPATE IN THIS STUDY
- Male and Female Active Duty members and DoD beneficiaries ages 18-65
- Moved to CREECH AFB from an altitude of less than 2,000 feet within the last month
Exclusion
- Preexisting depression as noted in a review of their medical record or on their PHQ9 (score of 10 or greater)
- Preexisting anxiety as noted in a review of their medical record or on their GAD 7 (score of 10 or greater)
- Clinical or laboratory evidence of liver disease.
- Serum creatinine \>1.5
- Existing kidney disease
- Existing Type I or Type II Diabetes Mellitus
- Taking creatine as a dietary supplement
- Moved to CREECH AFB from an altitude of greater than 2000 feet
- Pregnant, breast feeding, or trying to become pregnant
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 7 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03433651
Start Date
January 1 2019
End Date
January 7 2019
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mike O'Callaghan Military Medical Center
Las Vegas, Nevada, United States, 89191